XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
License Agreements - Syros (Details)
shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2018
item
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
License Agreements            
Fair market long term investments   $ 153,663,000   $ 153,663,000   $ 133,676,000 [1]
Unrealized gain (loss) on long term investments   $ (26,654,000) $ (660,000) $ 9,839,000 $ (72,142,000)  
Syros Pharmaceuticals, Inc.            
License Agreements            
Common stock held from investment (in shares) | shares   0.1   0.1    
Fair market long term investments   $ 400,000   $ 400,000   $ 300,000
Unrealized gain (loss) on long term investments   $ 100,000 $ (300,000) $ 0 $ (2,500,000)  
Syros Pharmaceuticals, Inc.            
License Agreements            
Number of program targets | item 7          
[1] The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date.